Inhibrx Biosciences CEO Mark Lappe reports acquisition of 10,040 common shares for $848,976.8365
Inhibrx Biosciences CEO and director Mark Lappe purchased 10,040 common shares through two trusts. Reported purchase prices were $84.0707, $84.9992 and $85.76 per share. His indirect beneficial ownership totaled 970,453 common shares following the purchases. Disclaimer: This news brief was created by Public Technologie